by admin | May 7, 2012 7:29 pm
Jeremy R. Degenhart joined Advantage Capital Partners in 2001. As a principal in the St. Louis office, Mr. Degenhart has a wide range of responsibilities including screening deal flow, conducting due diligence, negotiating transactions, managing existing investments and developing exit opportunities. Selected current and prior investments led by Mr. Degenhart include: Veran Medical Technologies; Singulex; Kereos; Prioria Robotics; The Lawrence Group; Stereotaxis, which held an initial public offering in 2004 (NASDAQ:STXS); and DataTrade, which sold to Goldleaf Financial in 2007.
Additionally, Mr. Degenhart is responsible for designing and analyzing new fundraising structures and facilitating their implementation. Mr. Degenhart participated in several of the first New Markets Tax Credit transactions ever closed in 2003-2004, at the inception of the program. He has continued to lead the structuring and closing of such financing transactions for Advantage Capital ever since. To date, Mr. Degenhart has been involved in providing in excess of $175 million of capital for more than 20 businesses. These companies have attracted an additional $425 million in follow-on capital, and currently employ over 1500 people.
Mr. Degenhart was the valedictorian of his undergraduate class at the John M. Olin Business School at Washington University in St. Louis, receiving a bachelor’s degree in finance, economics and accounting in May 2000. He has also earned the right to use the Chartered Financial Analyst designation.
Mr. Degenhart serves on the Board of Directors of the InvestMidwest Venture Capital Forum. He is a seasoned speaker, and he lectures on venture capital and private equity as an adjunct faculty member at the Olin Business School.
Source URL: http://www.advantagecap.com/jeremy-r-degenhart/
Copyright ©2015 Advantage Capital Partners unless otherwise noted.